Two hikers with backpacks and trekking poles on a rocky summit overlooking misty mountain valleys at sunrise

THE OUTLAST BLUEPRINT

DO WHAT YOU LOVE,
FOR LONGER.

Evidence-based training, recovery, and longevity — designed for athletes, builders, and anyone who wants to stay in the game for decades.

PERFORMANCE / RECOVERY / LONGEVITY

YOUR NEXT CHAPTER STARTS HERE

You're not done.
You're just getting started.

Maybe it's the trail you haven't returned to. The weights you stopped lifting. Or simply feeling like yourself again. Wherever you are, there's a place to begin.

Find your starting point

7 quick questions. About 60 seconds. No signup required.

010203

Recovery science

WHAT IF RECOVERY ISN'T AS SIMPLE AS HEALING?

Explore physical therapy, surgery, regenerative medicine, and emerging recovery research. Understand the evidence before the promises.

Explore recovery

THE SERIES

THE JOURNAL

WHY OUTLAST EXISTS

I'M NOT BACK TO 100%. BUT I'M NOT DONE.

From Division I basketball to broken bones, ACL injuries, surgeries, and an unfinished return to rugby. Outlast Blueprint was born from a personal question: how do we keep doing what we love for longer?

READ THE STORY

The Rebuild

Evidence-based insights for a longer, stronger you.

Plain-language research on performance, recovery, and longevity.

Sign up for The Rebuild

Educational emails on performance, recovery, and longevity.

Join the list for future issues of The Rebuild. Unsubscribe anytime. See our privacy policy.

Educational content only. Not medical advice.

Website transparency

Check Outlast Blueprint's website reputation on ScamAdviser.

The evidence behind the blueprint

Research Shelf

Original studies. Real findings. Read the evidence yourself.

  1. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

    Tested weekly retatrutide against placebo for weight loss over 48 weeks in adults with obesity.

    Human randomized trial · Phase 2 NEJM, 2023 Related article

    Read study
  2. Once-Weekly Semaglutide in Adults with Overweight or Obesity

    The STEP 1 trial: weekly semaglutide plus lifestyle intervention versus placebo for body weight.

    Human randomized trial · Phase 3 NEJM, 2021 Related article

    Read study
  3. Tirzepatide Once Weekly for the Treatment of Obesity

    The SURMOUNT-1 trial: three tirzepatide doses versus placebo for weight reduction over 72 weeks.

    Human randomized trial · Phase 3 NEJM, 2022 Related article

    Read study
  4. Association Between Sauna Bathing and Fatal Cardiovascular and All-Cause Mortality Events

    Followed Finnish middle-aged men and linked more frequent sauna use with lower mortality — an association, not proof of cause.

    Observational cohort study JAMA Internal Medicine, 2015 Related article

    Read study
  5. Whole-Body Hyperthermia for the Treatment of Major Depressive Disorder

    A small trial comparing a single whole-body heat session with a sham procedure for depressive symptoms.

    Human randomized trial · Small sample JAMA Psychiatry, 2016 Related article

    Read study

LATEST ARTICLES

VIEW ALL ARTICLES

FROM THE LAB

The science behind the playbook.

Outlast is the field guide. @atlasprephq is the science desk — deep peptide breakdowns, evidence-graded, no hype. That's where we source a lot of our peptide information.

Follow @atlasprephq